

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



瑋俊 生 物 科 技 有 限 公 司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHIEF EXECUTIVE OFFICER

Reference is made to the announcement of Wai Chun Bio-Technology Limited (the “**Company**”) dated 13 March 2023. The board of directors (the “**Board**”) of the Company is pleased to announce that Mr. Lam Ka Chun (“**Mr. Lam**”), currently an executive director of the Company, in addition to such role, has been appointed as chairman (“**Chairman**”) of the Board and chief executive officer of the Company (“**CEO**”) with effect from 1 November 2023.

Mr. Lam, aged 32, had studied chemistry at Imperial College London from 2009 to 2011 and he had served as chief executive officer in various companies from 2011 to 2017 which has accumulated extensive experience in projects investment and management. Mr. Lam has been the managing directors of the Company and Wai Chun Group Holdings Limited (stock code: 1013) (a company listed on the Main Board of the Stock Exchange) since 2017 and is responsible for the investment and operation of the listed companies. Mr. Lam has been appointed as the chairman of the board of directors, the chief executive officer and an executive director of Wai Chun Group Holdings Limited on 27 October 2023.

Mr. Lam is the son of Mr. Lam Ching Kui. As at the date of this announcement, Chinese Success Limited, the substantial shareholder of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”) and the controlling shareholder of the Company, is wholly owned by Wai Chun Investment Fund. Wai Chun Investment Fund is wholly owned by Mr. Lam Ching Kui.

Save as disclosed above, as at the date of this announcement, Mr. Lam (i) did not hold any position with the Company or other members of the Group; (ii) did not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this announcement and did not have any other major appointments and professional qualifications; (iii) did not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company; (iv) did not have any interest in the shares of the Company within the meaning of Part XV of the SFO; and (v) had no other information to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities (“**Listing Rules**”) on the Stock Exchange.

Save as disclosed above, there are no other matters that need to be brought to the attention of shareholders of the Company in relation to the appointment of Mr. Lam and there is no other information required to be disclosed pursuant to any of the requirements under Rule 13.51(2) of the Listing Rules.

The Board would like to welcome Mr. Lam as Chairman of the Board and CEO of the Company. The Board believes that his extensive commercial, strategic and operational experience together with his knowledge of the Company and its business, will enable him to provide leadership for the Board.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman and Chief Executive Officer

Hong Kong, 2 November 2023

As at the date of this announcement, the Board consists of one executive director, namely Mr. Lam Ka Chun (chairman and chief executive officer), and two independent non-executive directors, namely Ms. Hong Ting and Mr. Wan Bo.